Effectiveness and safety analysis of switching to tenofovir alafenamide after entecavir or tenofovir treatment

被引：0
|
作者：
Liu, Xue [1 ]
Zhao, Zhihao [1 ]
Kong, Xianggen [2 ]
Cui, Shiyu [2 ]
Jiang, Xuemei [2 ]
机构：
[1] Shandong Univ, Jinan, Peoples R China
[2] Shandong Publ Hlth Clin Ctr, Jinan, Peoples R China
来源：
JOURNAL OF HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
WED-415
引用
收藏
页码：S804 / S805
页数：2
相关论文
共 50 条
  • [31] Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B
    Kumada, Takashi
    Toyoda, Hidenori
    Yasuda, Satoshi
    Ito, Takanori
    Tanaka, Junko
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 : E898 - E904
  • [32] Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B
    Ishido, Shun
    Tamaki, Nobuharu
    Uchihara, Naoki
    Suzuki, Keito
    Tanaka, Yuki
    Miyamoto, Haruka
    Yamada, Michiko
    Matsumoto, Hiroaki
    Nobusawa, Tsubasa
    Keitoku, Taisei
    Takaura, Kenta
    Tanaka, Shohei
    Maeyashiki, Chiaki
    Yasui, Yutaka
    Takahashi, Yuka
    Tsuchiya, Kaoru
    Nakanishi, Hiroyuki
    Itakura, Jun
    Kurosaki, Masayuki
    Izumi, Namiki
    JGH OPEN, 2023, 7 (08): : 567 - 571
  • [33] Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B
    Kumada, Takashi
    Toyoda, Hidenori
    Yasuda, Satoshi
    Ito, Takanori
    Tanaka, Junko
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (1S) : E898 - E904
  • [34] Efficacy and safety of switching therapy from tenofovir disoproxil fumarate to tenofovir alafenamide for hepatitis B virus infection
    Kaneko, Shun
    Kurosaki, Masayuki
    Tamaki, Nobuharu
    Itakura, Jun
    Kirino, Sakura
    Watakabe, Keiya
    Osawa, Leona
    Okada, Mao
    Wan, Wang
    Shimizu, Takao
    Higuchi, Mayu
    Takaura, Kenta
    Yasui, Yutaka
    Tsuchiya, Kaoru
    Nakanishi, Hiroyuki
    Takahashi, Yuka
    Izumi, Namiki
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E469 - E469
  • [35] Switching to tenofovir alafenamide (TAF): why and when?
    Munatsi, S.
    Darley, A.
    Pammi, M.
    HIV MEDICINE, 2018, 19 : S86 - S86
  • [36] Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B
    Ogawa, Eiichi
    Nomura, Hideyuki
    Nakamuta, Makoto
    Furusyo, Norihiro
    Koyanagi, Toshimasa
    Dohmen, Kazufumi
    Ooho, Aritsune
    Satoh, Takeaki
    Kawano, Akira
    Kajiwara, Eiji
    Takahashi, Kazuhiro
    Azuma, Koichi
    Kato, Masaki
    Shimoda, Shinji
    Hayashi, Jun
    LIVER INTERNATIONAL, 2020, 40 (07) : 1578 - 1589
  • [37] Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters
    Corona, Diana
    Perez-Valero, Ignacio
    Camacho, Angela
    Liarte, Angela Gutierrez
    Montero-Alonso, Marta
    Aleman, Maria Remedios
    Ruiz-Seco, Pilar
    Gonzalez, Alexandre Perez
    Riera, Melchor
    Jarrin, Inmaculada
    Rivero-Juarez, Antonio
    Rivero, Antonio
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 63 (01)
  • [38] COMPARATIVE EFFICACY AND RENAL SAFETY OF ENTECAVIR, TENOFOVIR DISOPROXIL FUMARATE AND TENOFOVIR ALAFENAMIDE FOR HBV-INFECTED CANCER PATIENTS UNDERGOING CHEMOTHERAPY
    Lee, I-Cheng
    Lan, Keng-Hsin
    Su, Chien-Wei
    Chao, Yee
    Lin, Han-Chieh
    Hou, Ming-Chih
    Huang, Yi Hsiang
    HEPATOLOGY, 2021, 74 : 473A - 474A
  • [39] To use entecavir, tenofovir disoproxil fumarate or tenofovir alafenamide: it's all about choosing the right patient!
    Satsangi, Sandeep
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 30 (06) : 689 - 690
  • [40] Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy
    Huang, Chih-Wen
    Yang, Chen-Ta
    Su, Pei-Yuan
    Chen, Yang-Yuan
    Huang, Siou-Ping
    Yen, Hsu-Heng
    BIOMEDICINES, 2023, 11 (03)
12345